Biomarkers of the Response to CBT for Insomnia in Major Depression

CBT 治疗重度抑郁症失眠反应的生物标志物

基本信息

  • 批准号:
    7936298
  • 负责人:
  • 金额:
    $ 39.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-10-01 至 2013-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Untreated insomnia in those with major depressive disorder (MDD) increases risks of suicide, poor antidepressant response, and depressive relapse. Cognitive-behavioral therapy for insomnia (CBT) has established insomnia efficacy with advantages in terms of side-effects and durability of benefit over medication therapies but has slower onset of effect. However, we lack predictors of the CBT response that might help to optimally guide the choice of insomnia therapy. A key impediment in this regard is limited understanding of the therapeutic mechanisms of CBT that could provide a basis for the development of clinically useful predictors of response. This application proposes an ancillary study which aims to address this need by evaluating promising sleep EEG and genetic biomarkers of the response to CBT in individuals with insomnia comorbid with MDD. The parent study, a recently NIH-funded Phase III clinical trial, has a distinct aim of documenting that CBT enhances the depression response to antidepressant medication in 255 men and women with insomnia comorbid with MDD. The proposed study will test the hypothesis that homeostatic and arousal-related mechanisms that are reflected in sleep EEG measures and are affected by a few key genetic polymorphisms play a role in sleep disturbance in insomnia and are targeted by the components of CBT. This will be achieved by obtaining a small number of measures that will not adversely affect the parent study. Ultimately, this work could serve as the basis for the eventual development of individualized treatment of insomnia when present in the context of MDD, which could shorten the period of suffering and disability and minimize the number of patients treated with sleep medications, thus decreasing costs and side-effects and improving long-term outcome. PUBLIC HEALTH RELEVANCE: The administration of rapid and effective treatment for insomnia in those with MDD is critical in order to minimize suffering, disability, costs, and suicide risk. By evaluating potential biomarkers of the response to CBT for insomnia in MDD, the proposed study will improve our understanding of the mechanisms that play a role in sleep disturbance occurring in this setting and in the therapeutic effects of CBT. As a result, the proposed study could lead to novel insomnia therapies and, ultimately, could lead to means to increase the speed and durability of the response to antidepressant therapy and thereby result in clinically meaningful improvement in the lives of many patients with MDD and insomnia. (End of Abstract)
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW D KRYSTAL其他文献

ANDREW D KRYSTAL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW D KRYSTAL', 18)}}的其他基金

Responsive Neurostimulation for Treatment Resistant Depression
反应性神经刺激治疗难治性抑郁症
  • 批准号:
    10513243
  • 财政年份:
    2023
  • 资助金额:
    $ 39.13万
  • 项目类别:
Deciphering principles of network dynamics underlying depression symptom severity from multi-day intracranial recordings in patients with major depression
从重度抑郁症患者多日颅内记录中解读抑郁症症状严重程度的网络动态原理
  • 批准号:
    10321656
  • 财政年份:
    2021
  • 资助金额:
    $ 39.13万
  • 项目类别:
Tissue-Specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
阻塞性睡眠呼吸暂停中的组织特异性胰岛素抵抗:缺氧的作用
  • 批准号:
    9750700
  • 财政年份:
    2018
  • 资助金额:
    $ 39.13万
  • 项目类别:
Tissue-Specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
阻塞性睡眠呼吸暂停中的组织特异性胰岛素抵抗:缺氧的作用
  • 批准号:
    10242721
  • 财政年份:
    2018
  • 资助金额:
    $ 39.13万
  • 项目类别:
Tissue-Specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia
阻塞性睡眠呼吸暂停中的组织特异性胰岛素抵抗:缺氧的作用
  • 批准号:
    10693797
  • 财政年份:
    2018
  • 资助金额:
    $ 39.13万
  • 项目类别:
Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear
经颅直流电刺激 (tDCS) 治疗急性恐惧
  • 批准号:
    8874641
  • 财政年份:
    2015
  • 资助金额:
    $ 39.13万
  • 项目类别:
MGT SVCS/CONTRACT & PROCUREMENT SUP - New Experimental Medicine Studies: Fast-Fail Trials in Mood and Anxiety
MGT SVCS/合同
  • 批准号:
    8919169
  • 财政年份:
    2014
  • 资助金额:
    $ 39.13万
  • 项目类别:
2/3-Reducing Suicide Ideation Through Insomnia Treatment (REST-IT)
2/3-通过失眠治疗减少自杀意念 (REST-IT)
  • 批准号:
    8370417
  • 财政年份:
    2012
  • 资助金额:
    $ 39.13万
  • 项目类别:
2/3-Reducing Suicide Ideation Through Insomnia Treatment (REST-IT)
2/3-通过失眠治疗减少自杀意念 (REST-IT)
  • 批准号:
    8675289
  • 财政年份:
    2012
  • 资助金额:
    $ 39.13万
  • 项目类别:
2/3-Reducing Suicide Ideation Through Insomnia Treatment (REST-IT)
2/3-通过失眠治疗减少自杀意念 (REST-IT)
  • 批准号:
    8839298
  • 财政年份:
    2012
  • 资助金额:
    $ 39.13万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 39.13万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 39.13万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 39.13万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 39.13万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了